"You don't want to trigger pexophagy by mistake."
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Deciding what to eat C ells adapt to their surroundings by generating new organelles when needed and degrading them when they become damaged or superfl uous. Many organelles, including the ER and mitochondria, are turned over by autophagy-the "self-eating" pathway in which cytoplasmic contents are engulfed in a double-membraned vesicle and transported to the lysosome to be broken down and recycled. But, just like people, cells have to watch what they eat and ensure only the right organelles are degraded. Manjithaya et al. now reveal the signaling pathway that specifi cally stimulates the destruction of peroxisomes (1) .
Because peroxisomes contain the enzymes necessary for catabolizing fatty acids, yeast grown on oleate produce extra peroxisomes to exploit this carbon source. But switching the yeast to glucose-containing medium renders these peroxisomes redundant. In a process called pexophagy, cells dismantle their excess peroxisomes using their autophagic machinery (2) . "But how do you take a nonselective process like autophagy and make it only eat peroxisomes?" asks Suresh Subramani, from the University of California, San Diego.
Subramani and colleagues have identified factors that control the selective destruction of peroxisomes, including a protein called Atg30 that targets the organelles to the autophagy pathway (3). Little is known about the signaling events that control pexophagy, however, so Manjithaya et al. screened for yeast kinase mutants that couldn't eliminate their peroxisomes after switching from oleate to glucose media (1). The researchers discovered that the mitogen-activated protein kinase (MAPK) Slt2p was essential for peroxisome turnover. "Our assay was pexophagyspecifi c but we were concerned that this might be a general signaling pathway for all autophagic processes," says Subramani. "We were really excited to fi nd that Slt2p didn't affect general autophagy or the selective removal of other organelles."
Slt2p is at the bottom of a signaling cascade activated by damage to the yeast cell wall (4) . All of the upstream kinases in the pathway were also required for pexophagy, as was Mid2p-a cell surface protein that senses cell wall integrity and initiates signaling to Slt2p . But what does the cell wall have to do with peroxisome turnover?
In fact, activating the MAPK pathway wasn't sufficient to induce pexophagy. The team thinks that simultaneous activation of protein kinase A (PKA) by the entry of hexoses, such as glucose, into yeast cells is also required for peroxisome removal. The presence of glucose stimulates PKA by up-regulating cAMP levels and, Subramani speculates, activates Mid2p by inducing changes in the glycosylation pattern of cell wall proteins. The coincidence of these two signals causes cells to destroy their peroxisomes. "You don't want to trigger pexophagy by mistake," Subramani explains, "so you need signaling through both of these pathways."
How does Slt2p promote pexophagy? Manjithaya et al. found that peroxisomes were still engulfed into double-membraned "pexophagosomes" in cells lacking Slt2p, suggesting that this MAPK controls a later step in the pathway, such as transport to, or fusion with, the vacuole (the yeast equivalent of lysosomes). Although MAPKs often target transcription factors, Subramani thinks that Slt2p regulates pexophagy more directly by phosphorylating a protein on the pexophagosome surface. "That makes our task more diffi cult as it's likely to be a novel substrate," he adds. "But at least we know where to start looking."
Subramani is also interested in how the MAPK and hexose-sensing pathways are integrated, and to what extent this regulation is conserved across evolution. He suspects that the process may ultimately be linked to human disease-defects in both peroxisome biogenesis and autophagy contribute to a variety of disorders. "These are important proteins," Subramani says. "As we start to look at selective organelle turnover, there will be disease connections that we'll need to explore."
